Michael M. Millenson, MD
- Request Appointment
- Clinical Locations
- Education, Training & Credentials
- Patient Stories
- Research Profile
Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111
Director, Hematology Service
My focus is on the diagnosis and management of a broad spectrum of both malignant and benign hematologic conditions, including consultative hematology.
Emanuel Weinberger Prize, Temple University School of Medicine, 1984
Robert L. Krigel Memorial Award Recipient, Fox Chase Cancer Center, 1995, 2001, 2013
My basic philosophy is to treat each patient as I myself would wish to be treated, namely, with focused and personalized attention and shared decision making, respecting the goals and values of individual patients and their families, and with an emphasis on providing state of the art diagnosis and treatment. Working at Fox Chase allows me to offer an expert team approach to patient care, and provides access to many of the latest and most promising treatments for my patients.
- Fellow, Hematology-Oncology, Harvard Medical School, Boston, MA
- Fellow, Hematology-Oncology, Beth Israel Hospital, Boston, MA
- Resident, Internal Medicine, Temple University Hospital, Philadelphia, PA
- MD, Temple University School of Medicine, Philadelphia, PA, 1984
- ABIM Subspecialty Certification in Hematology, 1990, 2000 and 2010
- ABIM Subspecialty Certification in Medical Oncology, 1991, 2000 and 2010
- American Board of Internal Medicine, Internal Medicine, Hematology, Medical Oncology
- American Society of Clinical Oncology, 1996
- International Society on Thrombosis and Haemostasis, 1994
- American Society of Hematology, 1992
Roseann Tice says her husband always called her a "sunshine person."
"As long as the sun was shining I was happy, and I would enjoy the day. If it was rainy, cloudy or overcast - not so much," recalls Roseann. But now, after a 15-year journey with the professionals at Fox Chase Cancer Center, Roseann even loves the rainy days. As she says, "every day, regardless of the weather, is a great day, because I'm alive."
- Hematologic malignancies, including non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, chronic lymphocytic leukemia, multiple myeloma, myeloproliferative disorders, and myelodysplastic syndromes.
- Disorders of thrombosis and hemostasis, particularly in the cancer population.
Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015 Jan 22;372(4):311-9. doi: 10.1056/NEJMoa1411087. Epub 2014 Dec 6. PubMed; PubMed Central PMCID: PMC434800
Evens AM, Smith MR, Lossos IS, Helenowski I, Millenson M, Winter JN, Rosen ST, Gordon LI.Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study. Br J Haematol. 2014 Aug;166(4):514-20. doi: 10.1111/bjh.12915. Epub 2014 Apr 25. PubMed
Herrera AF, Crosby-Thompson A, Friedberg JW, Abel GA, Czuczman MS, Gordon LI, Kaminski MS, Millenson MM, Nademanee AP, Niland JC, Rodig SJ, Rodriguez MA, Zelenetz AD, LaCasce AS. Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network. Cancer. 2014 Jul 1;120(13):1993-9. doi: 10.1002/cncr.28676. Epub 2014 Apr 4. PubMed PMID: 24706502; PubMed Central PMCID: PMC4130379.
Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, Vanderplas A, Zelenetz AD, Abel GA, Rodriguez MA, Nademanee A, Kaminski MS, Czuczman MS, Millenson M, Niland J, Gascoyne RD, Connors JM, Friedberg JW, Winter JN. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014 Feb 6;123(6):837-42. doi: 10.1182/blood-2013-09-524108. Epub 2013 Nov 21. PubMed PMID: 24264230.
Ban-Hoefen M, Vanderplas A, Crosby-Thompson AL, Abel GA, Czuczman MS, Gordon LI, Kaminski MS, Kelly J, Millenson M, Nademanee AP, Rodriguez MA, Zelenetz AD, Niland J, LaCasce AS, Friedberg JW. Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database. Br J Haematol. 2013 Nov;163(4):487-95. doi: 10.1111/bjh.12570. Epub 2013 Sep 20. PubMed PMID: 24111533.
Streiff MB, Bockenstedt PL, Cataland SR, Chesney C, Eby C, Fanikos J, Fogerty AE, Gao S, Goldhaber SZ, Hassoun H, Hendrie P, Holmstrom B, Kuderer N, Lee JT, Millenson MM, Neff AT, Ortel TL, Siddiqi T, Smith JL, Yee GC, Zakarija A, McMillian N, Naganuma M; National comprehensive cancer network. Venous thromboembolic disease. J Natl Compr Canc Netw. 2013 Nov;11(11):1402-29. PubMed PMID: 24225973.
Shafer D, Smith MR, Borghaei H, Millenson MM, Li T, Litwin S, Anad R, Al-Saleem T. Low NK cell counts in peripheral blood are associated with inferior overall survival in patients with follicular lymphoma. Leuk Res. 2013 Oct;37(10):1213-5. doi: 10.1016/j.leukres.2013.07.038. Epub 2013 Aug 7. PubMed PMID: 23968916; PubMed Central PMCID: PMC3976217.
Greenberg PL, Attar E, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, Frankfurt O, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, O'Donnell MR, Shami PJ, Stein BL, Stone RM, Thompson JE, Westervelt P, Wheeler B, Shead DA, Naganuma M. Myelodysplastic syndromes: clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2013 Jul;11(7):838-74. PubMed PMID: 23847220; PubMed Central PMCID: PMC4000017.
Kumar A, Vanderplas A, LaCasce AS, Rodriguez MA, Crosby AL, Lepisto E, Czuczman MS, Nademanee A, Niland J, Gordon LI, Millenson M, Zelenetz AD, Friedberg JW, Abel GA. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database. Cancer. 2012 Jun 1;118(11):2944-51. doi: 10.1002/cncr.26588. Epub 2011 Oct 17. PubMed PMID: 22006274
Leonard JP, LaCasce AS, Smith MR, Noy A, Chirieac LR, Rodig SJ, Yu JQ, Vallabhajosula S, Schoder H, English P, Neuberg DS, Martin P, Millenson MM, Ely SA, Courtney R, Shaik N, Wilner KD, Randolph S, Van den Abbeele AD, Chen-Kiang SY, Yap JT, Shapiro GI. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.Blood. 2012 May 17;119(20):4597-607. doi: 10.1182/blood-2011-10-388298. Epub 2012 Mar 1. PubMed PMID: 22383795.